Skip to content
by Legal Desire
SIGN IN GO PRO
10 August 2026

Latham & Watkins Advises on BlossomHill Therapeutics’ Upsized US$150 Million IPO

Capital Markets & IPO Healthcare & Life Sciences Announced United States

Advising firms

Latham & Watkins LLP
Underwriters acting for underwriters

Deal team

16 lawyers named
LawyerFirmSeniorityPracticeOffice
Matt Bush Lead Latham & Watkins LLP Partner Capital Markets San Diego
Omeed Valipour Latham & Watkins LLP Associate Capital Markets Not stated
Sterling Swift Latham & Watkins LLP Associate Capital Markets Not stated
Madeline Hodges Latham & Watkins LLP Associate Capital Markets Not stated
Chad Jennings Latham & Watkins LLP Partner FDA matters Washington, D.C.
Trevor Thompson Latham & Watkins LLP Associate FDA matters Not stated
Betty Pang Latham & Watkins LLP Partner healthcare matters Bay Area
Holly Bauer Latham & Watkins LLP Partner executive compensation and employee benefits matters San Diego
Julie Voorhes Latham & Watkins LLP Associate executive compensation and employee benefits matters Not stated
Georgianna Chan Latham & Watkins LLP Associate executive compensation and employee benefits matters Not stated
Heather Deixler Latham & Watkins LLP Partner data privacy matters Bay Area
Zac Alpert Latham & Watkins LLP Associate data privacy matters Not stated
Robert Yeh Latham & Watkins LLP Counsel intellectual property matters San Diego
Arun Mohan Latham & Watkins LLP Associate intellectual property matters Not stated
Andrew Wang Latham & Watkins LLP Associate intellectual property matters Not stated
Eric Cho Latham & Watkins LLP Partner tax matters Los Angeles

13 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.

REGISTER FREE SIGN IN

Want co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.

Stated terms

Stated value
USD 150m (US$150.0 million)
What the figure measures
Issue size
Client
Not stated
Counterparties
BlossomHill Therapeutics, Inc. (Issuer)